Medicine guide

What is Ozempic?

Ozempic is a once-weekly semaglutide injection licensed in the UK for adults with insufficiently controlled type 2 diabetes, alongside diet and exercise. Its UK licence concerns diabetes rather than weight management. [1]

Published by GLP1GuideEditorial update How this page is prepared
On this page
  1. Start with the reason it was prescribed
  2. Why Ozempic is not another name for Wegovy
  3. Read the label, not a click chart
  4. Evidence beyond the bathroom scales
  5. Safety and diabetes monitoring
  6. When supply or instructions change
  7. Questions and answers
  8. Sources

At a glance

  • Ozempic and Wegovy share an ingredient but are different products.
  • Diabetes treatment is reviewed using more than body weight.
  • Use the instructions for the exact pen supplied to you.

Start with the reason it was prescribed

Ozempic can be used alone when metformin is unsuitable because of intolerance or a contraindication, or alongside other diabetes medicines. The purpose is to improve diabetes management; the prescription should fit into the rest of your care. [1]

At an appointment, ask which measurement will show whether the medicine is helping and when it will be reviewed. Write down the answer in the same place as your medicine list. If weight is also a concern, bring that into the discussion explicitly rather than assuming that every change in weight explains how well your diabetes is controlled.

The NHS semaglutide information highlights interactions and the need to tell the prescriber about other medicines, vitamins and supplements. This includes treatments obtained from another service. [2]

Why Ozempic is not another name for Wegovy

Semaglutide is the active ingredient; Ozempic and Wegovy are brand names with different authorised uses and product instructions. Wegovy now includes injectable and oral presentations. An ingredient match does not establish a matching dose, device or treatment schedule. [1][3]

Off-label prescribing means using a medicine outside the terms of its licence. It is a clinical decision with additional responsibilities, not a claim that the product has acquired another authorised use. [4] If that is proposed, ask why it is being considered, what alternatives exist and what information you need to make a decision.

For a comparison, put the complete product names side by side. “Semaglutide” alone is not specific enough for a supply calculation, and the number on one pen should not be used to interpret another pen's dial.

Read the label, not a click chart

UK Ozempic 1 mg information lists both four-dose and eight-dose pens, with different concentrations. Check the supplied presentation. [1] A similar appearance does not establish a matching amount per turn of the dial.

Follow the manufacturer instructions for selecting the prescribed dose. The leaflet warns against using the pen's clicks to count a dose. If a dose cannot be selected or you are uncertain whether it was delivered, contact the pharmacist or prescribing service instead of improvising an extra injection. [5]

Before leaving the pharmacy, confirm the number of labelled doses in your pack, what needle supplies are needed and where to find the disposal instructions. For cost comparisons, write down the pack price and its labelled treatments. A price “per pen” is incomplete without knowing which pen it describes.

Evidence beyond the bathroom scales

FLOW studied weekly semaglutide 1 mg in people with both type 2 diabetes and chronic kidney disease meeting defined trial criteria. It found a lower risk of its composite kidney and cardiovascular-death outcome than placebo. This is evidence in a specific higher-risk population, not proof that any semaglutide product prevents kidney disease in everybody. [6]

A composite endpoint combines several kinds of event into one trial measure. When reading a percentage reduction, ask which events were counted, who entered the study and what the comparator was. Those questions are more useful than treating a headline percentage as a personal forecast.

Safety and diabetes monitoring

Ozempic is not a replacement for insulin. Combining it with insulin or a sulfonylurea can increase the risk of low blood glucose, and the clinician may adjust those treatments. Do not make those adjustments independently. [5]

Discuss existing diabetic retinopathy and any change in vision. Separately, the MHRA warns of a very rare semaglutide-associated optic-nerve condition, NAION. Sudden sight loss or rapidly worsening vision needs urgent medical attention. [7]

Persistent severe abdominal pain can signal pancreatitis and needs urgent assessment. Vomiting or diarrhoea that prevents you keeping fluids down also warrants prompt advice. [8][9]

Keep the contact details for routine diabetes questions and urgent help in an accessible place. At review, bring the timing of symptoms, the strength used and any missed treatment dates. A short factual record is more useful than trying to remember everything after several weeks.

When supply or instructions change

If a pharmacy offers a replacement presentation, ask them to explain the differences before using it. If treatment is interrupted, ask the prescriber how to restart. Avoid buying a substitute through a social-media seller; the MHRA has identified fake Ozempic pens, including some containing insulin. [10]

Ask for a written plan that covers repeat prescriptions, reviews, storage during travel and questions about missed doses. The plan should identify which service is responsible, particularly if private care and NHS diabetes care are both involved.

Questions and answers

Is Ozempic licensed for weight loss in the UK?
Its current UK indication is treatment of adults with insufficiently controlled type 2 diabetes. Weight change does not turn that into a weight-management authorisation. [1]
Can I use a Wegovy dose schedule for Ozempic?
No. Use the prescription and leaflet for your exact product. The brands and presentations should not be substituted through a calculation. [5]
What should I bring to a diabetes review?
Your current medicine list, any glucose records you have been asked to keep, dates of treatment changes, and a brief account of symptoms or practical difficulties.

Sources

Sources consulted for this editorial update: 28 October 2026. Follow the link for the source’s own revision date.

  1. Ozempic: UK Summary of Product CharacteristicsUK product information updated July 2026; adult type 2 diabetes indication and presentation-specific dose volumes.
  2. NHS: semaglutidePatient information about uses, safety, interactions and practical treatment considerations.
  3. MHRA: first GLP-1 tablet for weight loss approved in the UK11 June 2026 authorisation announcement. Statements about NHS availability refer to the announcement date.
  4. MHRA: off-label and unlicensed prescribing responsibilitiesDefinitions of off-label use and responsibilities for assessment, communication and follow-up.
  5. Ozempic 1 mg: UK patient leafletPatient information and instructions for the stated Ozempic product; verify the leaflet supplied with each pack.
  6. FLOW: semaglutide in type 2 diabetes and chronic kidney diseasePrimary trial, 2024; semaglutide 1 mg injection in a defined diabetes and kidney-disease population. Funded by Novo Nordisk.
  7. MHRA: semaglutide and the very rare risk of NAION5 February 2026 safety update; sudden loss or rapid deterioration of vision requires urgent assessment.
  8. MHRA: updated guidance for GLP-1 prescribers and patients29 January 2026 patient-facing explanation of severe acute pancreatitis risk.
  9. NHS: dehydrationSigns of dehydration, fluids and oral rehydration, and when urgent help is needed.
  10. MHRA: falsified Ozempic and Saxenda products23 November 2023 safety alert, including insulin-containing fake pens and reporting advice.

This page is general information for UK readers. It cannot tell you which medicine or dose is suitable for you. Read the scope and limits.